Pharmacoeconomic review report: Omalizumab (Xolair)

Omalizumab is being reviewed for the treatment of adults and adolescents (12 years of age and older) with moderate-to-severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen, and whose symptoms are inadequately controlled with inhaled corticosteroids...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Published: Ottawa (ON) CADTH September 2017, 2017
Series:CADTH common drug review
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Table of Contents:
  • Includes bibliographical references